[go: up one dir, main page]

MX2011011477A - Derivados de isoxazol-piridazina. - Google Patents

Derivados de isoxazol-piridazina.

Info

Publication number
MX2011011477A
MX2011011477A MX2011011477A MX2011011477A MX2011011477A MX 2011011477 A MX2011011477 A MX 2011011477A MX 2011011477 A MX2011011477 A MX 2011011477A MX 2011011477 A MX2011011477 A MX 2011011477A MX 2011011477 A MX2011011477 A MX 2011011477A
Authority
MX
Mexico
Prior art keywords
isoxazole
pyridazine derivatives
present
cognitive
gaba
Prior art date
Application number
MX2011011477A
Other languages
English (en)
Inventor
Andrew Thomas
Matthew C Lucas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011011477A publication Critical patent/MX2011011477A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con derivados de isoxazol-piridazina que tienen afinidad y selectividad para el receptor GABA A a5, su fabricación, composiciones farmacéuticas que los contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos de la presente invención son útiles como potenciadores cognitivos o para el tratamiento terapéutico y/o profiláctico de trastornos cognitivos como enfermedad de Alzheimer.
MX2011011477A 2009-05-05 2010-04-28 Derivados de isoxazol-piridazina. MX2011011477A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159412 2009-05-05
PCT/EP2010/055669 WO2010127968A1 (en) 2009-05-05 2010-04-28 Isoxazole-pyridazine derivatives

Publications (1)

Publication Number Publication Date
MX2011011477A true MX2011011477A (es) 2011-11-18

Family

ID=42331035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011477A MX2011011477A (es) 2009-05-05 2010-04-28 Derivados de isoxazol-piridazina.

Country Status (13)

Country Link
US (1) US8410104B2 (es)
EP (1) EP2427458B1 (es)
JP (1) JP6026273B2 (es)
KR (1) KR101701533B1 (es)
CN (1) CN102414204B (es)
AU (1) AU2010244545A1 (es)
BR (1) BRPI1013762A2 (es)
CA (1) CA2760597C (es)
ES (1) ES2467701T3 (es)
IL (1) IL215109A0 (es)
MX (1) MX2011011477A (es)
SG (1) SG175780A1 (es)
WO (1) WO2010127968A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590542A (en) * 2008-06-19 2012-12-21 Xcovery Holding Co Llc Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
US8227461B2 (en) * 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2876778A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
AU2013283488A1 (en) * 2012-06-26 2015-01-15 Saniona Aps A phenyl triazole derivative and its use for modulating the GABAA receptor complex
KR20170004013A (ko) * 2014-06-03 2017-01-10 에프. 호프만-라 로슈 아게 옥시토신 작용제인 펩티드
CR20160562A (es) * 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
US20230130180A1 (en) 2020-01-10 2023-04-27 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
EP4087554A4 (en) 2020-01-10 2024-01-17 Pacira Pharmaceuticals, Inc. TREATMENT OF PAIN BY SUBARACHNOID ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETICAL COMPOSITIONS
CN116997338A (zh) 2021-01-11 2023-11-03 帕西拉制药股份有限公司 用缓释脂质体麻醉剂组合物治疗髋部疼痛
WO2022197899A2 (en) 2021-03-19 2022-09-22 Pacira Pharmaceuticals, Inc. Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525205A1 (de) * 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
US6511987B1 (en) 1999-11-12 2003-01-28 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EP1411942A4 (en) 2001-07-05 2005-01-26 Synaptic Pharma Corp SUBSTITUTED ANILINPIPERIDINES AS MCH-SELECTIVE ANTAGONISTS
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
ES2299618T3 (es) 2001-11-20 2008-06-01 Eli Lilly And Company Agonistas beta-3-adrenergicos.
GB0128160D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
WO2005118568A1 (en) 2004-06-01 2005-12-15 F. Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
EP1773807A2 (en) 2004-06-14 2007-04-18 Takeda San Diego, Inc. Kinase inhibitors
GB0418267D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
JP4620123B2 (ja) 2004-10-01 2011-01-26 エフ．ホフマン−ラ ロシュ アーゲー ヘキサフルオロイソプロパノール置換エーテル誘導体
EP1812427A4 (en) 2004-10-15 2009-10-14 Scripps Research Inst FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
ATE414703T1 (de) 2005-09-19 2008-12-15 Hoffmann La Roche Isoxazolderivate als inverse gaba a alpha5 agonisten
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
US7863302B2 (en) 2006-02-03 2011-01-04 Eli Lilly And Company Compounds and methods for modulating FX-receptors
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) * 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8227461B2 (en) * 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles

Also Published As

Publication number Publication date
WO2010127968A1 (en) 2010-11-11
EP2427458A1 (en) 2012-03-14
ES2467701T3 (es) 2014-06-12
KR101701533B1 (ko) 2017-02-13
BRPI1013762A2 (pt) 2015-08-25
US20100286159A1 (en) 2010-11-11
AU2010244545A1 (en) 2011-10-13
IL215109A0 (en) 2011-12-29
US8410104B2 (en) 2013-04-02
KR20120027204A (ko) 2012-03-21
SG175780A1 (en) 2011-12-29
CA2760597C (en) 2017-08-22
CN102414204A (zh) 2012-04-11
CA2760597A1 (en) 2010-11-11
JP2012526068A (ja) 2012-10-25
EP2427458B1 (en) 2014-05-07
CN102414204B (zh) 2014-12-31
JP6026273B2 (ja) 2016-11-16

Similar Documents

Publication Publication Date Title
MX2011011477A (es) Derivados de isoxazol-piridazina.
MX2011011489A (es) Derivados de isoxazol-piridina.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
MX2011011273A (es) Derivados de isoxazol-pirazol.
MX2009014001A (es) Derivados de isoxazol-imidazol.
EA200901373A1 (ru) Аминогетероциклические соединения
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
IN2012DN00766A (es)
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
TW201144302A (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
MY177111A (en) Substituted amide derivatives and methods of use
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
EP2037739A4 (en) BENZYL-SUBSTITUTED POSITIVE ALLOSTERIC CHINOLON M1 RECEPTOR MODULATORS
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
IL190867A0 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.

Legal Events

Date Code Title Description
FG Grant or registration